The role of Bcl-2 family members in non-small cell lung cancer

Seminars in Thoracic and Cardiovascular Surgery

Volumn 16, Issue 1, 2004, Pages 19-27

  Daniel, Jonathan C ^a   Smythe, W Roy ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 385358; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DACARBAZINE; DOCETAXEL; FOMIVIRSEN; HA 141; MITOXANTRONE; OBLIMERSEN; PACLITAXEL; PHOSPHOROTHIOIC ACID; PROTEIN BCL 2; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; CANCER GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; FEVER; GENE FUNCTION; HALF LIFE TIME; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SEQUENCE HOMOLOGY; SOLID TUMOR; SURGEON; THORAX SURGERY; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM;

EID: 2642555698     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2004.01.002     Document Type: Review

References (66)

1. Degli EM: Apoptosis: Who was first. Cell Death Diff 5:719, 1998
2. Kerr JF, Wyllie AH, Currei AR: Apoptosis: a Basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257, 1972
3. Hockenberry D, Nunex G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990
4. Reed JC, Miyashita T, Takayama S, et al: BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer resistance to Therapy. J Cell Biochem 60:23-32, 1996
5. Sartorius UA, Krammer PH: Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97:584-592, 2002
6. Decaudin D, Geley S, Hirsch T, et al: Bcl-2 and Bcl-xl antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57:62-67, 1997
7. Adams JM, Cory S: The bcl-2 protein family: Arbiters of cell survival. Science 281:1322-1326, 1998
8. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1975-2000. Bethesda, MD, National Cancer Institute, 2003
9. Jiang SX, Sato Y, Kuwao S, et al: Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas J Pathol 177:135-138, 1995
10. Ohsaki Y, Toyoshima E, Fujiuchi S, et al: Bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res 2:915-920, 1996
11. Pezzella F, Turley H, Kuzu I, et al: bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 329:690-694, 1993
12. Higashiyama M, Doi O, Kodama K, et al: Bcl-2 oncoprotein in surgically resected nonsmall cell lung cancer: Possibly favorable prognostic factor in association with low incidence of distant metastasis. J Surg Oncol 64:48-54, 1997
13. Cox G, Jones JL, Andi A, et al: Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer 34:417-426, 2001
14. Moldvay J, Scheid P, Wild P, et al: Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 6:1125-1134, 2000
15. Borner MM, Brousset P, Pfanner-Meyer B, et al: Expression of apoptosis regulatory proteins of the bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 79:952-958, 1999
16. Poleri C, Morero JL, Nieva B, et al: Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma. Chest 123:1858-1867, 2003
17. Pastorino U, Andreola S, Tagliabue E, et al: Immunocytochemical markers in stage I lung cancer: Relevance to prognosis J Clin Oncol 15:2858-2865, 1997
18. Huang C, Neuberg D, Johnson BE, et al: Expression of bcl-2 protein is associated with shorter survival in non-small cell lung carcinoma. Cancer 98:135-143, 2003
19. Tomita M, Matsuzaki Y, Edagawa M, et al: Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol 29:654-657, 2003
20. Mai H, May WS, Gao F, et al: A functional role for nicotine in bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 278:1886-1891, 2003
21. Martin B, Pacsmans M, Berghmans T, et al: Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 89:55-64, 2003
22. Krug LM, Miller VA, Filippa DA, et al: Bcl-2 and bax expression in advanced non-small cell lung cancer: Lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung Cancer 39:139-143, 2003
23. Brooks KR, To K, Joshi MB, et al: Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 76:187-193, 2003
24. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, et al: Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer 74: 565-570, 1997
25. Poommipanit PB, Chen B, Oltvai ZN: Interleukin-3 induces the phsophorylation of a distinct fraction of bcl-2. J Biol Chem 274:1033-1039, 1999
26. Reeve JG, Xiong J, Morgan J, et al: Expression of apoptosis-regulatory genes in lung tumor cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer 73:1193-200, 1996
27. Soini Y, Kinnula V, Wiik-Kaarteenaho R, et al: Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-x and bax in malignant mesothelioma. Clin Can Res 5:3508-3515, 1999
28. Motoyama N, Wang F, Roth KA, et al: Massive cell death of immature hematopoietic cells and neurons in bcl-xl deficient mice. Science 267:1506-1510, 1995
29. Veis DJ, Sorenson CM, Shutter JR, et al: Bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229-240, 1993
30. Caputi M, Groeger AM, Esposito V, et al: Frequent high expression of bax pro-apoptotic protein in non-small cell lung cancer. Anticancer Res 19:825-827, 1999
31. Apolinario RM, Van der valk P, De Jong JS, et al: Prognostic value of the expression of p53, bcl-2 and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer. J Clin Oncol 15:2456-2466, 1997
32. Gessner C, Lieber U, Kuhn H, et al: Bax and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 19:134-140, 2002
33. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucledotide. Proc Natl Acad Sci USA 75: 280-284, 1978
34. Koty PP, Zhang H, Levitt M: Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 23:115-127, 1999
35. Koty PP, Tyurina YY, Tyurin VA, et al: Depletion of Bcl-2 by an antisense oligonucleotide induces apoptosis accompanied by oxidation and externalization of phosphatidylserine in NCI-H226 lung carcinoma cells. Mol Cell Biochem 234(-235):125-133, 2002
36. Jansen B, Wacheck V, Heere-Ress E, et al: Chemosensitisation of malignant melanoma by bcl2 antisense therapy. Lancet 356:1728-1733, 2000
37. Zangemeister-Wittke U, Schenker T, Luedke GH, et al: Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78:1035-1042, 1998
38. Leech SH, Olie RA, Gautschi O, et al: Induction of apoptosis in lung cancer cells following bcl-xl antisense treatment. Int J Cancer 86:570-576, 2000
39. Smythe WR, Mohuiddin I, Ozveran M, et al: Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 123:1191-1198, 2002
40. Taylor JK, Qing QZ, Wyatt JR, et al: Induction of endogenous bcl-xs through the control of bcl-x pre-mRNA splicing by antisense oligonucleotides. Nature Bio 17:1097-1100, 1999
41. Zangemeister-Wittke U, Leech SH, Olie RA, et al: A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xl expression efficiently induces apoptosis in tumor cells. Clin Can Res 6:2547-2555, 2000
42. Gautschi O, Tschopp S, Olie R, et al: Activity of a novel bcl-2/bcl-xl-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Can Inst 93: 463-471, 2001
43. Cao X, Gu J, Miller SD, et al: A bcl-xl antisense adenoviral vector: a novel and effective pro-apoptolic gene therapy construct. 5th Annual Meeting of the American Society of Gene Therapy, Boston, MA, June, 2002
44. Kagawa S, Gu J, Swisher S, et al: Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53 resistance cancer lines. Cancer Res 60:1157-1161, 2000
45. Groeger AM, Esposito V, Cassandro R, et al: A model of Bax gene delivery to human lung cancer. Anticancer Res 21:3627-30, 2001
46. Kaliberov SA, Buchsbaum DJ, Gillespie GY, et al: Adenovirus-mediated transfer of Bax driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol Ther 6:190-198, 2002
47. Daniel JC, Smythe WR: Gene therapy of lung cancer. Semin Surg Oncol 21:196-204, 2003
48. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619, 1993
49. Shangary S, Johnson DE: Peptides derived from BH3 domains of Bcl-2 family members: A comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochemistry 4:9485-9495, 2002
50. Degterev A, Lugovskoy A, Cardone M, et al: Identification of small-molecule inhibitors of interaction between the BH3 domain and bcl-xl. Nat Cell Biol 3:173-182, 2001
51. Feng W, Liu F, Patwari Y, et al: BH3-domain mimetic compound BH3I-2′ induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria. Brit J Hem 121:332-340, 2003
52. Wang J, Liu D, Zhang Z, et al: Structure-based discovery of an organic compound that hinds Bcl-2 protein and induces apoptosis of tumor cells. Proc Nat Acad Sci 97: 7124-7129, 2000
53. Shoemaker A, Oleksijew A, Qing W, et al: Anti-tumor activity of A-385358: A small molecule inhibitor of Bcl-xl. Proc Am Assoc Can Res 44:1317abstr, 2003
54. McKnight KL, Heinz BA: RNA as a target for developing antivirals. Antivir Chem Chemother Mar 14:61-73, 2003
55. Freedman SB: Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr Opin Lipidol 13: 653-661, 2002
56. Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Opthalmol 133:484-498, 2002
57. Waters J, Webb A, Cunningham D, et al: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non Hodgkin's lymphoma. J Clin Oncol 18:1812-1823, 2000
58. Morris MJ, Tong WP, Cardo-Cordon C, et al: Phase I trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8:679-683, 2002
59. Jansen B, Schlagbauer-Wadl H, Brown BD, et al: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232-234, 1998
60. Jansen B, Wacheck V, Heere-Ress E, et al: Chemosensitisation of malignant melanoma by BCL-2 antisense therapy. Lancet 356:1728-33, 2000
61. Rudin CM, Otterson GA, Mauer AM, et al: A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 13:539-545, 2002
62. Chi KN, Gleave ME, Klasa R, et al: A Phase I dose finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7:3920-3927, 2001
63. Chen H, Marshall J, Trocky N, et al: A phase I study of BCL-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Proc Am Soc Clin Oncol 692, 2000 (abstr)
64. Yang E, Korsemeyer SJ: Molecular thanatopsis: a disclosure on the bcl-2 family and cell death. Blood 88:386-401, 1996
65. Swisher SG, Roth JA, Komaki R, et al: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9:93-101, 2003
66. Elbashir SM, Harborth J, Lendeckel W, et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498, 2001